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Abstract
Background: Cancer stem cells (CSCs) can proliferate and self-renew extensively due to their ability to express anti-apoptotic
and drug resistant proteins, thus sustaining tumor growth. Therefore, the strategy to eradicate CSCs might have significant
clinical implications. The objectives of this study were to examine the molecular mechanisms by which resveratrol inhibits
stem cell characteristics of pancreatic CSCs derived from human primary tumors and Kras
G12D transgenic mice.
Methodology/Principal Findings: Human pancreatic CSCs (CD133
+CD44
+CD24
+ESA
+) are highly tumorigenic and form
subcutaneous tumors in NOD/SCID mice. Human pancreatic CSCs expressing high levels of CD133, CD24, CD44, ESA, and
aldehyde dehydrogenase also express significantly more Nanog, Oct-4, Notch1, MDR1 and ABCG2 than normal pancreatic
tissues and primary pancreatic cancer cells. Similarly, CSCs from Kras
G12D mice express significantly higher levels of Nanog
and Oct-4 than pancreatic tissues from Pdx-Cre mice. Resveratrol inhibits the growth (size and weight) and development
(PanIN lesions) of pancreatic cancer in Kras
G12D mice. Resveratrol inhibits the self-renewal capacity of pancreatic CSCs
derived from human primary tumors and Kras
G12D mice. Resveratrol induces apoptosis by activating capase-3/7 and
inhibiting the expression of Bcl-2 and XIAP in human CSCs. Resveratrol inhibits pluripotency maintaining factors (Nanog,
Sox-2, c-Myc and Oct-4) and drug resistance gene ABCG2 in CSCs. Inhibition of Nanog by shRNA enhances the inhibitory
effects of resveratrol on self-renewal capacity of CSCs. Finally, resveratrol inhibits CSC’s migration and invasion and markers
of epithelial-mesenchymal transition (Zeb-1, Slug and Snail).
Conclusions/Significance: These data suggest that resveratrol inhibits pancreatic cancer stem cell characteristics in human
and Kras
G12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. In
conclusion, resveratrol can be used for the management of pancreatic cancer.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer death in
the United States. It is expected that approximately 32,000
Americans will die from pancreatic cancer this year. With an
overall 5-year survival rate of 3% [1], pancreatic cancer has one of
the poorest prognoses among all cancers [2]. Aside from its silent
nature and tendency for late discovery, pancreatic cancer also
shows unusual resistance to chemotherapy and radiation. Only
20% of pancreatic cancer patients are eligible for surgical resection
[3]. The operations are very complex, and unless performed by
surgeons specially trained and experienced in this procedure, they
can be associated with very high rates of operative morbidity and
mortality. Unfortunately, many pancreatic cancers are not
resectable at the time of diagnosis. Furthermore, there are limited
treatment options available for the patients with pancreatic cancer
because chemo- and radio-therapies are largely ineffective, and
metastatic disease frequently redevelops even after surgery.
Therefore, there is an urgent need to discover novel and effective
approaches for the prevention and/or treatment of pancreatic
cancer.
It is now being realized that tumors contain a small number of
tumor-forming and self-renewing cancer stem cells (CSCs) within a
population of nontumor-forming cancer cells [4]. We and other
have identified CSCs in several types of human cancers including
pancreatic cancer [5,6,7,8,9]. Cancer stem cells hypothesis suggest
that conventional chemotherapies kill differentiated or differenti-
ating cells, and these cells form the bulk of the tumor, but can not
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remain untouched, suggesting the removal of CSCs is very crucial
for effective cancer therapy. Unlike most cells within the tumor,
CSCs, including pancreatic CSCs, are resistant to chemotherapy
and may contribute to tumor metastasis and tumor recurrence
after treatment. Therefore, drugs that selectively target CSCs offer
a greater promise for cancer therapy and/or prevention.
Epidemiological and dietary intervention studies in animals and
humans have suggested that diet-derived phenolics, in particular
the flavonoids, may play a beneficial role in inhibiting, reversing or
retarding tumorigenesis in many types of cancers, including
pancreatic cancer [10]. The polyphenolic compound resveratrol is a
naturally occurring phytochemical and is found in many plant
species, including grapes, peanuts and various herbs [10].
Resveratrolhasbeen showntohave anti-inflammatory,antioxidant,
antitumor, neuroprotective and immunomodulatory activities
[10,11,12,13,14]. It also has activity in the regulation of multiple
cellular events associated with carcinogenesis [10,11,12,13,14]. Its
anticancer effects in pancreatic cancer include its ability to inhibit
cell proliferation and angiogenesis, and induce apoptosis in pre-
clinical studies [15,16,17,18,19,20]. Resveratrol can enhance
antitumor activity of gemcitabine in vitro and in orthotopic mouse
model of human pancreatic cancer [19]. We and others have
demonstrated that resveratrol enhances the therapeutic potential of
anticancer drugs and sensitizes cancer cells to chemotherapy and
radiotherapy [10,19,21,22,23]. Although these studies have exam-
ined the affect of resveratrol on pancreatic cancer, there are no
studies examining how resveratrol regulates pancreatic cancer stem
cell characteristics.
Epithelial cells undergo fibroblastoid morphological changes
associated with increased motility or invasiveness due to decreased
cell-cell adhesion (11–14). Fibroblastoid morphological changes of
epithelial cells are known as epithelial-to-mesenchymal transition
(EMT). EMT induction in cancer cells results in the acquisition of
invasive and metastatic properties [24,25,26,27,28]. Recent
reports indicate that the emergence of CSCs occurs in part as a
result of EMT, for example, through cues from tumor stromal
components. CSCs and EMT-type cells, which shares molecular
characteristics with CSCs, have been believed to play critical roles
in drug resistance and early cancer metastasis as demonstrated in
several human malignancies including pancreatic cancer
[27,29,30]. Thus, the discovery of molecular knowledge of drug
resistance and metastasis in relation to CSCs and EMT in
pancreatic cancer is becoming an important area of research, and
suchknowledgeis likelytobe helpfulinthediscoveryofnewerdrugs
as well as designing novel therapeutic strategies for the treatment
and/or prevention of pancreatic cancer with better outcome.
The objectives of our study were to examine the molecular
mechanisms by which resveratrol inhibits pancreatic CSC
characteristics in human and Kras
G12D transgenic mouse model,
and examine whether inhibition of Nanog enhances the ability of
resveratrol to inhibit self-renewal capacity of human pancreatic
CSCs.
Results
Isolation and characterization of human pancreatic CSCs
isolated from human primary pancreatic tumors
Tumors contain a small number of tumor-forming and self-
renewing CSCs within a population of nontumor-forming cancer
cells [4]. Therapeutic failure/recurrence is due to ineffective
targeting of CSC population. The CD44
+CD24
+ESA
+ pancreatic
cancer cells are highly tumorigenic and possess the stem cell-like
properties of self-renewal and the ability to produce differentiated
progeny [31]. From a therapeutic point of view, CSCs in several
tumor types have shown resistance to standard therapies and may
play a role in treatment failure or disease recurrence. Identification
of pancreatic CSCs and further elucidation of the signaling
pathways that regulate their growth and survival may provide
novel therapeutic and preventive approaches for the management
of pancreatic cancer. We first characterized CSCs isolated from
human pancreatic tumors (Fig. 1A–H). Pancreatic CSCs express
stem cell markers CD44, ESA, CD133, and CD24, and
pluripotency maintaining factor Oct-4. Pancreatic CD44
+E-
SA
+CD133
+CD24
+ CSCs also expressed ALDH (aldehyde
dehydrogenase), another marker for CSCs.
We next examined the expression of stem cell markers
(CD133
+CD44
+CD24
+ESA
+), pluripotency maintaining factors
(Nanog), signaling molecule (Notch-1) and drug resistant genes
(MDR1 and ABCG2) in human normal pancreas, primary
pancreatic cancer cells, and CSCs by q-RT-PCR (Fig. 1I). Normal
pancreatic tissues express very low levels of CD133, CD24, CD44,
ESA, Nanog, Notch1, MDR1 and ABCG2 compared to
pancreatic cancer and CSCs. Human pancreatic tumors expressed
about 3–6% CSCs. By comparison, the expression of these genes
in pancreatic cancer cells was significantly lower than CSCs.
Interestingly, CD133
+CD44
+CD24
+ESA
+ CSC express higher
levels of Nanog, Notch1, MDR1 and ABCG2 genes.
Tumorigenic potential of CD133
+CD44
+CD24
-ESA
+
pancreatic CSCs in NOD/SCID mice
We next compared the tumorigenic potential of
CD133
2CD44
2CD24
2ESA
2 pancreatic CSCs with that of
CD133
+CD44
+CD24
2ESA
+ pancreatic CSCs isolated from hu-
man primary tumors in NOD/SCID mice (Fig. 2). Nude mice were
injected with 50 CD44
2CD44
2CD24
2ESA
2 CSCs and
CD133
+CD44
+CD24
+ESA
+ CSCs in left and right flanks, respec-
tively. The data demonstrated that CD133
+CD44
+CD24
+ESA
+
CSCs formed tumors in 20 days in NOD/SCID mice, whereas
CD133
2CD44
2CD24
2ESA
2 CSCs did not form tumors (Fig. 2A).
H&E staining of CD44
+CD24
+ESA
+ CSC tumors formed in nude
mice revealed similar tumor phenotype with that of primary human
tumors (Fig. 2B). The expressions of S100P and Stratifin were also
similar in primary tumors and pancreatic CSCs. These data suggest
that CD133
+CD44
+CD24
+ESA
+CSCs aretumorigenic, and posses
CSC characteristics.
Resveratrol inhibits the formation of primary and
secondary spheroids and cell viability of human
pancreatic CSCs
CSCs were grown in pancreatic cancer stem cell defined
medium in suspension, and treated with resveratrol for 7 days. At
the end of incubation period, spheroids in each well were
photographed. Resveratrol inhibited the growth of spheroids in
suspension in a dose-dependent manner (Fig. 3A). The spheroids
from each treatment group were collected and resuspended for
counting cell viability. Resveratrol inhibited pancreatic CSC
viability in a dose-dependent manner (Fig. 3B).
Since resveratrol inhibited the growth of tumor spheroid and
cell viability of CSCs, we next sought to examine the effects of
resveratrol on colony formation. Pancreatic CSCs were grown
in agar, and treated with various doses of resveratrol for 3
weeks. At the end of incubation period, colonies were counted.
Resveratrol inhibited the growth of colonies in a dose-dependent
manner (Fig. 3C). These data suggest that resveratrol can be
effective in inhibiting the self-renewal capacity of human
pancreatic CSCs.
Resveratrol Inhibits Pancreatic Cancer Stem Cells
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and inhibits the expression of XIAP, Bcl-2 and cyclin D1 in
pancreatic CSCs
We next examined the effects of resveratrol on caspase-3/-7
activity, apoptosis, and expression of apoptosis- and cell cycle-related
proteins (Fig. 4). Resveratrol induces caspase-3/-7 activity and
apoptosis (Fig. 4A and B). Since IAPs, Bcl-2 family members and
cyclin D1 play major roles in regulation of apoptosis and cellcycle, we
examined the effects of resveratrol on the expression of XIAP, Bcl-2,
caspase-3 and cyclin D1. Resveratrol inhibited the expression of
XIAP, Bcl-2 and cyclin D1, and also cleaved caspase-3 (Fig. 4C and
D). These data suggest that resveratrol causes growth arrest and
induces apoptosis in pancreatic CSCs through inhibition of cyclin D1
and apoptosis-related proteins (XIAP and Bcl-2), respectively.
Resveratrol inhibits the expression of Nanog, Sox-2,
cMyc, Oct-4 and ABCG2 in human pancreatic CSCs
Since transcription factors Nanog, Sox-2, cMyc and Oct-4 are
highly expressed in CSCs and are required for maintaining
pluripotency, we examined the effects of resveratrol on the
expression of Nanog, Sox-2, cMyc and Oct-4 in human pancreatic
CSCs expressing CD44
+/CD24
+/ESA
+ (Fig. 5). Resveratrol
inhibited the expression of Nanog, Sox-2 and cMyc as measured
by qRT-PCR (Fig. 5A). Similarly, resveratrol inhibited the
expression of Nanog, Oct-4 and Sox-2 in pancreatic CSCs as
measured by the Western blotting (Fig. 5B). Resveratrol also
inhibited the Nanog reporter activity (Fig. 5C). These data suggest
that resveratrol inhibits the factors required for maintaining
pluripotency in pancreatic CSCs.
Cancer stem cells have been shown to exhibit drug resistance
properties by expressing multidrug resistance genes such as
ABCG2. We therefore measured the expression of ABCG2 in
human CSCs treated with resveratrol. Resveratrol inhibited the
expression of ABCG2 in pancreatic CSCs as measured by qRT-
PCR (Fig. 5D). These data suggest that inhibition of ABCG2 by
resveratrol could be beneficial in enhancing the biological effects
of resveratrol alone or in combination with other drugs.
Nanog shRNA enhances the inhibitory effects of
resveratrol on pancreatic CSC viability in spheroids
Since Nanog is highly expressed in pancreatic CSCs, we sought
to examine whether inhibition of Nanog enhances the biological
Figure 1. Isolation and characterization of human pancreatic CSCs from human primary tumors. (A–H), Pancreatic cancer cells were
isolated from primary tumors and analyzed by flow cytometry using antibody against CD44, CD24, ESA, CD133, Oct4, and ALDH. (I), Expression of
stem cell markers. RNA was isolated from normal pancreatic tissues, primary pancreatic cancer and pancreatic CSCs and the expression of CD24,
CD133, CD44, ESA, Nanog, Notch1, MDR1 and ABCG2 was measured by q-RT-PCR. Data represent mean 6 SD. *, ** @ = significantly different from
controls, P,0.05.
doi:10.1371/journal.pone.0016530.g001
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Transduction of Nanog shRNA in CSCs inhibited Nanog
expression, as shown by the western blot analysis (Fig. 6A).
Resveratrol inhibited cell viability in spheroids (scrambled shRNA)
in a dose-dependent manner (Fig. 6B). Transduction of Nanog
shRNA further enhanced the inhibitory effects of resveratrol on
cell viability in spheroids. These data suggest that inhibition of
Nanog can enhance the chemopreventive effects of resveratrol.
Resveratrol inhibits markers of epithelial-mesenchymal
transition, invasion and migration in human pancreatic
CSCs
Epithelial to mesenchymal transitions (EMT) are transdiffer-
entiation programs that are required for tissue morphogenesis
during embryonic development [32]. The EMT process can be
regulated by a diverse array of cytokines and growth factors, such
as TGFb, whose activities are dysregulated during malignant
tumor progression [33]. Thus, EMT induction in cancer cells
results in the acquisition of invasive and metastatic properties.
Recent reports indicate that the emergence of CSCs occurs in part
as a result of EMT, for example, through cues from tumor stromal
components. EMT plays a crucial role in tumorigenesis, cancer
progression and drug resistance [28,32,34]. Recent studies
revealed that there is a direct link between the EMT program
and the gain of epithelial stem cell properties [28,32,34,35]. EMT
is sufficient to induce a population with stem cell characteristics
from well-differentiated epithelial cells and cancer cells. We next
examined the effects of resveratrol on the expression of EMT
markers in pancreatic CSCs (Fig. 7). Resveratrol inhibited the
expression of Zeb-1, Snail and Slug. Resveratrol also inhibited
invasion and migration of pancreatic CSCs (Fig. 7D and E). These
data suggest that resveratrol can regulate EMT, invasion and
migration by inhibiting the expression of Zeb-1, Snail and Slug in
CSCs.
Resveratrol inhibits the growth and development of
pancreatic cancer in Kras
G12D mice
Pancreatic ductal adenocarcinoma (PDAC) is characterized by
mutations in Kras and frequent deregulation of crucial embryonic
signaling pathways. The Kras
G12D mice develop spontaneous
tumors in the pancreas, and it truly resembles the growth of
human pancreatic cancers [36]. In Pdx1-Cre;LSL-Kras
G12D
(Kras
G12D) mice, physiological levels of Kras
G12D induce ductal
lesions that recapitulate the full spectrum of human PanINs,
Figure 2. Tumorigenic potential of pancreatic CSCs in NOD/SCID mice. (A), NOD/SCID mice were sc injected with 50
CD133
2CD44
2CD24
2ESA
2 cells on right flank and CD133
+CD44
+CD24
+ESA
+ CSCs on left flanks and tumor growth was observed for 20 days. (B),
Pancreatic CSCs are similar to human primary tumors. Tumor sections from human primary pancreatic tumors, and pancreatic CSCs grown in NOD/
SCID mice were stained with H&E, Statifin and S100P.
doi:10.1371/journal.pone.0016530.g002
Resveratrol Inhibits Pancreatic Cancer Stem Cells
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16530putative precursors to invasive pancreatic cancer. We therefore
examined the effects of resveratrol on pancreatic carcinogenesis in
Kras
G12D mice (Fig. 8). Resveratrol inhibited the growth of
pancreas (weight and size) in Kras
G12D mice compared to that of
untreated control (Fig. 8A and B). The mean weight of pancreas
from Kras
G12D mice was similar to that of Pdx1-Cre mice.
Quantifications of PanIN lesions in pancreas from Kras
G12D
mice treated with or without resveratrol for about 10 months (age
about 12 months) are shown in Fig. 8C. Untreated (control)
Kras
G12D mice showed various stages of cancer development
ranging from PanIN-1A to PanIN-3 stages. By comparison,
treatment of Kras
G12D mice with resveratrol significantly inhibited
pancreatic cancer development as evident by reduced numbers of
PanIN-1A, PanIN-1B and PanIN-2 lesions. Interestingly, resver-
atrol treated Kras
G12D mice showed no PanIN 3 lesions. These
data suggest that resveratrol inhibits the growth and development
of pancreatic cancer in Kras
G12D transgenic mice.
Resveratrol inhibits self-renewal capacity of pancreatic CSCs
We next examined whether the pancreas of Kras
G12D transgenic
mouse harbor cancer stem cells, and whether resveratrol inhibits
pancreatic CSCs in these mice. Treatment of Kras
G12D mice with
resveratrol completely eradicated pancreatic CSCs in Kras
G12D
mice at 12 months of age. Pancreatic CSCs isolated from Kras
G12D
mice express high levels of stem cell markers (CD133, CD44, CD24
and ESA) and transcription factors (Nanog and Oct-4) (Fig. 9A).
The expression of these markers in untreated Kras
G12D was
significantly higher than Pdx-Cre mice. Pancreatic tumors ex-
pressed about 1.3–2.5% CSCs isolated from 12 months old
Kras
G12D (control/untreated) mice. Since we have not seen any
pancreatic CSCs in resveratrol treated mice, we sought to examine
whether CSCs from control/untreated Kras
G12D mice are capable
of self-renewing and respond to resveratrol in vitro (Fig. 9B).
Resveratrol inhibited the self-renewal capacity of pancreatic CSCs
as measured by formation of primary and secondary spheroids in
Figure 3. Resveratrol inhibits cell viability in spheroids and colony formation by pancreatic CSCs. (A), Human pancreatic CSCs were
grown in six-well ultralow attachment plates (Corning Inc., Corning, NY) at a density of 1,000 cells/ml in Celprogen pancreatic CSC medium at 37uCi n
a humidified atmosphere of 95% air and 5% CO2 and treated with resveratrol (0–30 mM) for 7 days to obtain primary spheroids. At the end of
incubation period, spheroids were collected, reseeded and treated with resveratrol for another week to obtain secondary spheroids. (B) Cell viability
in spheroids was measured by trypan blue assay at the end of 7 and 14 days from above experiment. Data represent mean 6 SD. *, &, #, % and @ =
significantly different from controls, P,0.05. (C), Pancreatic CSCs were seeded in soft agar and treated with resveratrol (0–30 mM) for 21 days. At the
end of incubation period, numbers of colonies were counted. Data represent mean 6 SD. *, % and & = significantly different from control, P,0.05.
doi:10.1371/journal.pone.0016530.g003
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that resveratrol is effective in inhibiting the self-renewal capacity of
pancreatic CSCs derived from Kras
G12D mice.
Discussion
Cancer stem cells (CSCs) have been identified in a growing
number of malignancies and are functionally defined by their
ability to undergo self-renewal and produce differentiated progeny
[37,38]. These properties allow CSCs to recapitulate the original
tumor when injected into immunocompromised mice. CSCs
within an epithelial malignancy were first described in breast
cancer and found to display specific cell surface antigen expression
(CD44+CD24low/-) [39]. Since then, CSCs have been identified
in an increasing number of other human malignancies using CD44
and CD24 as well as a number of other surface antigens.
Physiologic properties, including aldehyde dehydrogenase (ALDH)
activity, have also been used to isolate CSCs from malignant
tissues [31,39,40,41,42,43,44]. Stem cells gain the quiescent
phenotype by regulating cell cycle proteins and pluripotent
stemness factors. Cancer stem/progenitor cells may exhibit
characteristics similar to normal stem cells. Thus, stem cells are
attractive candidates for cancer-initiating cells since their longevity
and self-renewal capability may result in the accumulation of
genetic mutations.
Our study demonstrates, for the first time, that cancer
preventive agent resveratrol can inhibit the self-renewal capacity
of pancreatic cancer stem cells derived from human primary
tumors and Kras
G12D mice in vitro. We were unable to observe
any pancreatic cancer stem cells in Kras
G12D mice treated with
resveratrol. However, resveratrol inhibited the formation of
primary and secondary spheroids in pancreatic cancer stem cells
isolated from Kras
G12D mice in vitro. Resveratrol induces apoptosis
by activating capase-3/7 and inhibiting the expression of Bcl-2,
and XIAP in CSCs. Interestingly, resveratrol also inhibits the
expression of ABCG2, a multidrug resistance gene which has been
demonstrated to overexpress in CSCs. Furthermore, resveratrol
inhibits epithelial-mesenchymal transition by inhibiting the
expression of vimentin, slug and snail, and also retards CSC’s
migration and invasion. These data suggest that resveratrol can be
used to prevent pancreatic cancer.
We have recently demonstrated that sulforaphane inhibited self-
renewal capacity of pancreatic cancer stem cells as measured by
spheroid and colony formation [7]. Sulforaphane inhibited the
expression of pluripotent transcription factors (Nanog, Oct-4 and
Sox-2). Inhibition of Nanog by lentiviral-mediated shRNA
expression enhanced the self-renewal capacity of sulforaphane.
Sulforaphane induced apoptosis by inhibiting the expression of Bcl-
2 and XIAP, phosphorylation of FKFR, and activating caspase-3
[7]. Moreover, sulforaphane inhibited expression of proteins
involved in the epithelial-mesenchymal transition (b-catenin,
vimentin, twist-1, and ZEB1), suggesting the blockade of signaling
involved in early metastasis. Furthermore, combination of quercetin
with sulforaphane, had synergistic effects on self-renewal capacity of
Figure 4. Resveratrol activates caspase-3/-7, induces apoptosis, and inhibits the expression of XIAP, Bcl-2 and cyclin D1 in
pancreatic CSCs. (A and B), Activation of caspase-3/-7 and induction of apoptosis. Pancreatic CSCs were treated with resveratrol (0–30 mM) for 48 h,
and caspase-3/-7 activity and apoptosis were measured by colorometric and TUNEL assay, respectively. Data represent mean 6 SD. *, & and # =
significantly different from control, P,0.05. (C and D), Pancreatic CSCs were treated with resveratrol (0–20 mM) for 48 h, and western blot analysis was
performed to measure the expression of XIAP, Bcl-2, caspase-3 and cyclin D1. GAPDH was used as a loading control.
doi:10.1371/journal.pone.0016530.g004
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or in combination with quercetin can eliminate cancer stem cell-
characteristics. Similarly in the present study, resveratrol inhibited
self-renewal capacity of pancreatic CSCs.
CSCs share principle characteristics with adult stem cells
namely self-renewal, high proliferative potential, clonogenicity,
and multipotency [45,46,47]. In addition, they have the ability to
reproducibly form the same tumor phenotype as in the patient and
to undergo differentiation into non-tumorigenic cells [48,49,50].
CSCs were first isolated from patients with hematologic
malignancies in which a few cells could initiate a new tumor
[51]. During the past few years, CSCs were also identified and
isolated from solid tumors such as breast, brain, colon, pancreatic,
and prostate tumors [29,39,44,52,53,54,55,56]. In pancreatic
cancer, CD44+/CD133+ pancreatic CSCs been identified
[57,58]. Because of the observed heterogeneity in pancreatic
cancer, the use of single-cell markers for the selection, character-
ization/identification, and functional evaluation of stem/progen-
itor-like pancreatic cancer cells will not be appropriate. Deregu-
lation of ALDH enzyme activity is implicated in the
pathophysiology of various hematologic and epithelial cancers
[40,59,60,61,62,63,64]. The introduction of FACS-based viable
cell sorting for ALDH activity (ALDEFLUOR assays) in tumor
biology has further substantiated a role of ALDH
hi subpopulations
of cancer cells in carcinogenesis [40,54,60,65]. High ALDH
activity, as detected by the ALDEFLUOR assay, can thus be used
as a functional marker to isolate CSCs in several types of epithelial
cancers, including those of ovarian, breast, lung, pancreatic and
colon [40,54,60,63,65,66]. Recently, CSCs from pancreatic
adenocarcinoma based on ALDH activity and the expression of
the CD44 and CD24, and CD133 have been identified
[31,43,67,68]. These highly tumorigenic populations may or
may not be overlapping and display other functions. It has been
reported that ALDH(+) and CD44(+)CD24(+) pancreatic CSCs
are similarly tumorigenic, but ALDH(+) cells are relatively more
invasive and possess metastatic behavior [68]. Similarly in the
present study, we have been able to isolate CD133, CD44, CD24,
ESA and ALDH positive pancreatic CSCs and demonstrated their
Figure 5. Inhibition of Nanog, Sox-2, cMyc, Oct-4 and ABCG2 in human pancreatic CSCs by resveratrol. (A), Pancreatic CSCs were
treated with resveratrol (0–20 mM) for 24 h. The expression of Nanog, Sox-2 and cMyc was measured by qRT-PCR. Data represent mean 6 SD. * and
@ = significantly different from control, P,0.05. (B), Pancreatic CSCs were treated with resveratrol (0–30 mM) for 48 h. The expression of Nanog, Oct-
4 and Sox-2 was measured by the Western blot analysis. GAPDH was used as a loading control. (C), Inhibition of Nanog transcription by resveratrol.
Pancreatic CSCs were transduced with Nanog reporter construct. Transduced cells were treated with resveratrol to examine the Nanog transcriptional
activity. Data represent mean 6 SD. *, #, @, & and ** = significantly different from control, P,0.05. (D), Pancreatic CSCs were treated with resveratrol
(0–30 mM) for 36 h. The expression of ABCG2 was measured by qRT-PCR. Data represent mean 6 SD. * and # = significantly different from control,
P,0.05.
doi:10.1371/journal.pone.0016530.g005
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hypothesis has provided a paradigm shift in our understanding of
carcinogenesis, metastasis, and tumor biology. The identification
of CSCs has important implications for designing new therapeutic
approaches for the treatment and prevention of cancer. The
involvement of CSCs in the formation of distant metastases, tumor
dormancy and therapy resistance offers high hopes for treating
cancer patients.
Recent evidence suggests a shared genomic fingerprint between
embryonic stem cells, cancer cells, and cancer stem cells.
Activation targets of Nanog, Oct-4, Sox2 and c-Myc are more
frequently overexpressed in certain tumors. In the absence of bona
fide cancer stem cell lines, human embryonic stem cells, which
have similar properties to cancer and cancer stem cells, have been
an excellent model throwing light on the anticancer affects of
various putative anticancer agents. Nanog, Sox2 and Oct-4 are
transcription factors which are essential to maintaining the
pluripotent embryonic stem cell phenotype. Oct-4 and Sox2 bind
to the Nanog promoter in living mouse and human ESCs [69].
Nanog, Oct-4 and Sox2 co-occupy and regulate their own
promoters together with other developmental genes with diverse
functions and collaborate to form an extensive regulatory circuitry
including autoregulatory and feed-forward loops [69,70,71]. A
high level of Nanog is a key regulator of ESC self-renewal and
puripotency. Nanog-deficient ES cells and embryos lose their
pluripotency [72]. Nanog overexpression leads to the clonal
expansion of ES cells through circumvention of the LIF-dependent
Stat-3 pathway and sustained Oct-4 expression levels [72,73].
Genome-wide gene expression profiling shows that Nanog is
expressed at high levels in testicular carcinoma in situ and germ
cell tumors [74]. Positive correlations of Oct-4, Nanog, or CD133
expression on tumor stage were shown on oral squamous cell
carcinoma patient tissues [75]. We have recently demonstrated
that inhibition of Nanog by shRNA enhanced the inhibitory effects
of EGCG and SFN on self-renewal capacity of CSCs, suggesting
its requirement for self-renewal of CSCs [6,7]. Medulloblastoma-
associated CSCs selected by serum-free medium with bFGF and
EGF can form 3D spheroids and display enhanced self-renewal
and highly co-expressed stem cell genes (Oct4, Nanog, Nestin, and
Musashi-1) as well as anti-apoptotic genes (Bcl-2 and Bcl-XL) [76].
These finding suggest that inhibition of pluripotency maintaining
transcription factor such as Nanog could be a novel strategy to kill
CSCs.
During EMT, epithelial cells lose their characteristics and gain
mesenchymal features. It has been suggested that transformed
epithelial cells can activate embryonic programs of epithelial
plasticity and switch from a sessile, epithelial phenotype to a
motile, mesenchymal phenotype. Induction of EMT can,
therefore, lead to invasion of surrounding stroma, intravasation,
dissemination and colonization of distant sites. Under the cancer
stem cell hypothesis, sustained metastatic growth requires the
dissemination of a CSC from the primary tumor followed by its re-
establishment in a secondary site. SNAI, ZEB and TWIST family
members repress the CDH1 gene to induce EMT, but also regulate
the transcription of other target genes. TWIST1 is upregulated in
human breast cancer, gastric cancer, esophageal cancer, and
prostate cancer. E-cadherin, occludin and cytokeratin are
downregulated during EMT, while N-cadherin, vimentin, fibro-
nectin, SNAI1/SAIL, SNAI2/SLUG, ZEB2/SIP1, and TWIST1
are upregulated [77]. E-cadherin and N-cadherin are representa-
tive adhesion molecules expressed on epithelial cells and
mesenchymal cells, respectively. E-cadherin at the adherens
junction is implicated in the stable cell-cell contact of epithelial
cells, while N-cadherin in the weak intercellular contact of
mesenchymal cells [78,79]. Class switch from E-cadherin to N-
cadherin results in the loss of epithelial phenotype and the
acquisition of mesenchymal phenotype. Transcriptional repression
of CDH1 gene or functional repression of E-cadherin protein is the
critical step for EMT. Upregulation of EMT regulators is
associated with more malignant phenotypes in a variety of human
cancer, such as gastric cancer, pancreatic cancer, breast cancer,
and ovarian cancer. In the present study, resveratrol inhibited the
expression of Snail, Slug and Zeb-1 in pancreatic cancer stem
cells. Similarly in our other studies, we have demonstrated that
EGCG and sulforaphane inhibited the expression of EMT
markers (expression of vimentin, nuclear b-catenin and TCF-1/
LEF reporter activity) and also inhibited the transcription factors
slug and snail [6,7]. The inhibition of EMT markers by these
agents suggests that they could inhibit early metastasis of
pancreatic CSCs.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by
near-universal mutations in Kras and frequent deregulation of
crucial embryonic signaling pathways. The Kras
G12D mice develop
spontaneous tumors in the pancreas, and it truly resembles the
growth of human pancreatic cancers [36]. In Pdx1-Cre;LSL-
Kras
G12D (Kras
G12D) mice, physiological levels of Kras
G12D induce
ductal lesions that recapitulate the full spectrum of human PanINs,
putative precursors to invasive pancreatic cancer. In the present
study using KrasG12D mice, resveratrol inhibited the weight of
pancreas, which was similar to that of Pdx1-Cre mice. Further-
more, untreated (control) Kras
G12D transgenic mice at 12 months
Figure 6. Nanog shRNA enhances the inhibitory effects of
resveratrol on self-renewal capacity of pancreatic cancer stem
cells. (A), Expression of Nanog. Pancreatic CSCs were transduced with
scrambled or Nanog shRNA, and Western blot analyses were performed
to examine the expression of Nanog and GAPDH. (B), Transduced cells
were treated with resveratrol (0–30 mM) and spheres in suspension
were grown for one week. Spheres were harvested, resuspended and
cell viability was determined by trypan blue assay.
doi:10.1371/journal.pone.0016530.g006
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PanIN-1A to PanIN-3 stages. By comparison, treatment of
Kras
G12D mice with resveratrol significantly inhibited pancreatic
cancer development as evident by reduced numbers of PanIN-1A,
PanIN-1B and PanIN-2 lesions. Interestingly, resveratrol treated
Kras
G12D mice showed no PanIN 3 lesions. Pancreatic CSCs
isolated from Kras
G12D mice express high levels of stem cell
markers (CD133, CD44, CD24 and ESA) and transcription
factors (Nanog and Oct-4). The expression of these markers in
untreated Kras
G12D was significantly higher than Pdx-Cre mice.
We were unable to detect any CSCs in resveratrol treated
Kras
G12D Mice. However, resveratrol inhibited the self-renewal
capacity of pancreatic CSCs isolated from Kras
G12D mice, as
measured by formation of primary and secondary spheroids in
suspension, and cell viability in those spheroids. These data suggest
that resveratrol (i) inhibits growth (weight and size) and
development (PanINS stages) of pancreatic cancer in Kras
G12D
transgenic mice, and (ii) inhibits the self-renewal capacity of
pancreatic CSCs derived from Kras
G12D mice.
In conclusion, we have demonstrated that resveratrol inhibited
self-renewal capacity of pancreatic CSCs isolated from human
primary cancer and Kras
G12D mice, Resveratrol inhibited the
pancreatic cancer growth and development (PanIN lesions) in
Kras
G12D mice, and also inhibited the expression of transcription
factors which are required for maintaining pluripotency. Further-
more, inhibition of Nanog could be considered as a novel strategy
to enhance the biological effects of anticancer and chemopreven-
tive agents or sensitize those cells which are resistant to
chemotherapy or irradiation. Moreover, resveratrol inhibited
invasion, migration and the expression of proteins involved in
the EMT, suggesting the blockade of signaling involved in early
metastasis. These data suggest that resveratrol can be used for the
prevention and/or treatment of pancreatic cancer.
Methods
Ethics statement
Experiments were conducted under approved protocols by the
Institutional Animal Care and Use Committee (IACUC) at the
University of Texas Health Science Center at Tyler (protocol
#372), and at Celprogen (protocol IRB # 1070080-00).
Reagents
Antibodies against vimentin, slug, snail, GAPDH, XIAP,
caspase-3, cyclin D1, Bcl-2, Oct-4, Sox-2, and Nanog were
purchased from Cell Signaling Technology, Inc. (Danvers, MA).
Figure 7. Regulation of EMT markers, invasion and migration by resveratrol in pancreatic CSCs. Pancreatic CSCs were treated with
resveratrol (0–0 mM) for 24 h. The expression of Zeb-1 (A), Snail (B) and Slug (c) was measured by the qRT-PCR. Data represent the mean 6 S.D. * or #
= significantly different from respective controls, P,0.05. (D), Invasion assay. Pancreatic CSCs were plated onto the Matrigel-coated membrane in the
top chamber of the transwell and treated with resveratrol (0–30 mM) for 48 h. Cells invaded to the lower chambered were fixed with methanol,
stained with crystal violet and counted. Data represent mean 6 SD. *, & or # = significantly different from control, P,0.05. (E) Migration assay.
Pancreatic CSCs were plated in the top chamber of the transwell and treated with resveratrol (0–30 mM) for 24 h. Cells migrated to the lower
chambered were fixed with methanol, stained with crystal violet and counted. Data represent mean 6 SD. *, & or # = significantly different from
control, P,0.05.
doi:10.1371/journal.pone.0016530.g007
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MN). The Aldefluor assay kit was purchased from Stem Cell
Technologies (Vancouver, BC). Enhanced chemiluminescence
(ECL) Western blot detection reagents were purchased from
Amersham Life Sciences Inc. (Arlington Heights, IL). All other
chemicals were purchased from Sigma-Aldrich (St Luis, MO).
Cell Culture
Human pancreatic cancer stem cells (CSCs) were cultured in
either Celprogen’s pancreatic CSC medium or DMEM supple-
mented with 1% N2 Supplement (Invitrogen), 2% B27 Supple-
ment (Invitrogen), 20 ng/ml human platelet growth factor (Sigma-
Aldrich), 100 ng/ml epidermal growth factor (Invitrogen) and 1%
antibiotic-antimycotic (Invitrogen) at 37uC in a humidified
atmosphere of 95% air and 5% CO2.
Tumor Spheroid Assay
Spheroid forming assays were performed as described elsewhere
[31,80]. In brief, single cells were plated in six-well ultralow
attachment plates (Corning Inc., Corning, NY) at a density of
1,000 cells/ml in DMEM supplemented with 1% N2 Supplement
(Invitrogen), 2% B27 Supplement (Invitrogen), 20 ng/ml human
platelet growth factor (Sigma-Aldrich), 100 ng/ml epidermal
growth factor (Invitrogen) and 1% antibiotic-antimycotic (Invitro-
gen) at 37uC in a humidified atmosphere of 95% air and 5% CO2.
Spheroid were collected after 7 days and dissociated with Accutase
(Innovative Cell Technologies, Inc.). The cells obtained from
dissociation were sieved through a 40-mm filter, and counted by
coulter counter using trypan blue dye.
Soft agar colony assay
Cell suspensions (2,500 cells) were prepared using 0.4% Noble
agarose (Becton Dickinson) and overlayed onto a 60-mm dish
containing a solidified bottom layer of 0.6% agarose in medium.
Once the top layer solidified, 1 ml of medium was placed on top of
the cell layer. After treatment, plates were incubated for 3 weeks
and colonies were counted.
Transwell Migration assay
For transwell migration assays, 1610
5 prostate CSCs were
plated in the top chamber onto the noncoated membrane (24-well
insert; pore size, 8 mm; Corning Costar) and allowed to migrate
toward serum-containing medium in the lower chamber. Cells
were fixed after 24 hours of incubation with methanol and stained
with 0.1% crystal violet (2 mg/mL, Sigma-Aldrich). The number
of cells invading through the membrane was counted under a light
microscope (406, three random fields per well).
Transwell invasion assay
For invasion assay, 1610
5 cells were plated in the top chamber
onto the Matrigel coated Membrane (24-well insert; pore size,
8 mm; Corning Costar). Each well was coated freshly with Matrigel
(60 mg; BD Bioscience) before the invasion assay. Cells were plated
in medium without serum or growth factors, and medium
supplemented with serum was used as a chemo-attractant in the
lower chamber. The cells were incubated for 48 hours and cells
that did invade through the pores were removed by a cotton swab.
Cells on the lower surface of the membrane were fixed with
methanol and stained with crystal violet. The number of cells
invading through the membrane was counted under a light
microscope (406, three random fields per well).
Viral production and infection
Nanog shRNA construct (pLKO.1-puro, Mission RNAi) was
from Open Biosystems. Lentiviral-TOP-dGFP-reporter (pRRL.sin-
18.ppt) has been described elsewhere [81]. Lentivirus was produced
Figure 8. Resveratrol inhibits pancreatic cancer growth and
development in Kras
G12D mice, and pancreatic CSC character-
istics. (A), Inhibition of pancreatic cancer growth by resveratrol. Kras
G12D
transgenic mice were treated with resveratrol (40 mg/kg) by gavage
once everyday (Monday – Friday) for about 10 months (mice age 12
months). Pancreas weights from control and resveratrol treated mice
were taken. Weight of pancreas from Pdx-cre mice was also taken. (B)
Picture of pancreas obtained from control and resveratrol treated
Kras
G12D mice. (C), Quantification of PanIN lesions in the pancreas of
control andresveratrol treatedKras
G12Dmice.Datarepresentthe mean 6
S.D. *, @, %, # = significantly different from respective controls, P,0.05.
doi:10.1371/journal.pone.0016530.g008
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collected and concentrated by ultracentrifugation to produce virus
stocks with titers of 1610
8 to 1610
9 infectious units per milliliter.
Viral supernatant was collectedfor three days by ultracentrifugation
and concentrated 100-fold [82]. Titers were determined on
HEK293T cells. Human prostate CSCs were transduced with a
mixture of viral particles and polybrene with two rounds of
infections [82].
Caspase-3/7 Assay
Cells (3610
4 per well) were seeded in a 96-well plate with 200 ml
culture medium. Approximately 16 h later, cells were treated with
various doses of resveratrol. Casapse-3/7 activity was measured by
a fluorometer as per manufacturer’s instructions (Invitrogen).
Western Blot Analysis
Western blots were performed as we described earlier [23,83].
In brief, cells were lysed in RIPA buffer containing 1 X protease
inhibitor cocktail, and protein concentrations were determined
using the Bradford assay (Bio-Rad, Philadelphia, PA). Proteins
were separated by 12.5% SDS/PAGE and transferred to
membranes (Millipore, Bedford, MA) at 55 V for 4 h at 4uC.
After blocking in 5% nonfat dry milk in TBS, the membranes were
incubated with primary antibodies at 1:1,000 dilution in TBS
overnight at 4uC, washed three times with TBS-Tween 20, and
then incubated with secondary antibodies conjugated with
horseradish peroxidase at 1:5,000 dilution in TBS for 1 hour at
room temperature. Membranes were washed again in TBS-Tween
20 for three times at room temperature. Protein bands were
visualized on X-ray film using an enhanced chemiluminescence
detection system.
Quantitative real-time reverse transcription-PCR
For the determination of gene expression levels, RNA was
extracted from cells using trizol and treated with DNase I (Sigma).
Total RNA (1 mg) was retrotranscribed using the ImProm-II
Reverse Transcription System (Promega). SYBR Green I
quantitative real-time reverse transcription-PCR (qRT-PCR) was
performed, and the housekeeping gene GAPDH was used to
normalize the variation in cDNA levels. SYBR Green I
amplifications were performed using the GeneAmp 7000 Se-
quence Detection System (Applied Biosystems). Custom primers
for Nanog, Sox-2, cMyc, ABCG2, Zeb1, Snail and Slug were
purchased from realtime primers.com.
Figure 9. Resveratrol inhibits the pancreatic cancer stem cell characteristics Kras
G12D mice. (A), Pancreatic CSCs were isolated from
Kras
G12D mice (about 12 months old) using CD133, CD44, CD24, and ESA antibodies. The expression of these markers and Nanog and Oct-4 was
confirmed by qRT-PCR. Data represent mean 6 SD. * = significantly different from the same gene of Pdx-Cre mice at P,0.05. (B), CSCs were grown in
suspension and treated with resveratrol (0–30 mM) for 7 days to obtain primary spheroids. At the end of incubation period, spheroids were collected,
resuspended and treated with resveratrol for another week to obtain secondary spheroids. Cell viability in spheroids was measured by trypan blue
assay at the end of 7 and 14 days. Data represent mean 6 SD. *, %, &, ** and ## = significantly different from respective controls, P,0.05.
doi:10.1371/journal.pone.0016530.g009
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G12D Mice
LSL K-ras
G12D and Pdx-1-Cre mice were obtained from the
National Cancer Institute (Frederick, MD). LSL K-ras
G12D mice
were crossed with the Pdx-1-Cre mice to obtain Kras
G12D (Pdx1-
Cre;LSL-Kras
G12D) mice. The recombined Kras
G12D allele was
identified by PCR. Pdx1-Cre;LSL-Kras
G12D mice develop early
stage PanIN lesions at 2 months of age and the vast majority of
ducts are normal [36]. However, mice develop statistically
significant numbers of advanced PanIN lesions (stages 2 and 3)
about 7 months, and the vast majority of ducts are abnormal [36].
Beginning at approximately this age, these mice also typically
begin to develop invasive and metastatic pancreatic ductal
adenocarcinoma.
Statistical Analysis
The mean and SD were calculated for each experimental
group. Differences between groups were analyzed by one or two
way ANOVA, followed by Bonferoni’s multiple comparison tests
using PRISM statistical analysis software (GrafPad Software, Inc.,
San Diego, CA). Significant differences among groups were
calculated at P,0.05.
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